We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

At the end of the Teva

7 February 2017 By Neil Unmack

The Israeli pharmaceuticals company has lost its second chief executive in four years. Its next CEO faces tough times in America, where drugmakers’ pricing is under attack. Homegrown problems include bad acquisitions, tricky governance and an over-reliance on one drug.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)